Immune Design announces positive topline data from three phase 1 clinical trials
Immune Design reported analyses of data from three ongoing Phase 1 studies support continued development of its two primary product candidates, CMB305 and G100. CMB305 and G100 represent two distinct approaches to fighting cancer via the in vivo induction and/or expansion of anti-tumor CD8 T cells. March 31, 2015